Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion

Derrell M. Wilson; Susan N. Perkins; James A. Thomas; Steven Seelig; Susan A Berry; Thomas E. Hamm; Andrew R. Hoffman; Raymond L. Hintz; Ron G. Rosenfeld

doi:10.1016/0026-0495(89)90180-7

Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion

Derrell M. Wilson, Susan N. Perkins, James A. Thomas, Steven Seelig, Susan A Berry, Thomas E. Hamm, Andrew R. Hoffman, Raymond L. Hintz, Ron G. Rosenfeld

Pediatric Genetics & Metabolism

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P < .0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.

Original language	English (US)
Pages (from-to)	57-62
Number of pages	6
Journal	Metabolism
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/0026-0495(89)90180-7
State	Published - Jan 1989

Bibliographical note

Funding Information:
From the Department of Pediatrics, Medicine, and Laboratory Animal Medicine, Stanford University. Stanford, CA. and the Department of Pediatrics, University of Minnesota, MN. Presented in part to the American Federation of Clinical Research. Western Section, Carmel. CA, February 1987. Supported in part by NIH grant Nos. DK32817. DK38480. lP40RRO3624-01, lR24RRO259601. DK28229, DK36054. AGO1312. and DK24085. and the American Institute for Cancer Research. Dr. Thomas is a recipient of a Science Research Program award of the March of Dimes Birth Defects Foundation. Dr. Rosenfeld is a recipient of a Research Career Development Award from the NIH (DKO1275). Dr. Perkins is a recipient of a NRSA (DKO7768). Address reprint requests to Dr. Darrell M. Wilson, S-322, Stanford University Medical Center, Stanford, CA 94305. o 1989 by Grune & Stratton, Inc. 0026-0495/89/3801-0009$03.00/O

Publisher link

10.1016/0026-0495(89)90180-7

Find It

Find It at U of M Libraries

Cite this

@article{258382df2f4b4f739cd0d33596f67c3f,

title = "Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion",

abstract = "The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P < .0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.",

author = "Wilson, {Derrell M.} and Perkins, {Susan N.} and Thomas, {James A.} and Steven Seelig and Berry, {Susan A} and Hamm, {Thomas E.} and Hoffman, {Andrew R.} and Hintz, {Raymond L.} and Rosenfeld, {Ron G.}",

note = "Funding Information: From the Department of Pediatrics, Medicine, and Laboratory Animal Medicine, Stanford University. Stanford, CA. and the Department of Pediatrics, University of Minnesota, MN. Presented in part to the American Federation of Clinical Research. Western Section, Carmel. CA, February 1987. Supported in part by NIH grant Nos. DK32817. DK38480. lP40RRO3624-01, lR24RRO259601. DK28229, DK36054. AGO1312. and DK24085. and the American Institute for Cancer Research. Dr. Thomas is a recipient of a Science Research Program award of the March of Dimes Birth Defects Foundation. Dr. Rosenfeld is a recipient of a Research Career Development Award from the NIH (DKO1275). Dr. Perkins is a recipient of a NRSA (DKO7768). Address reprint requests to Dr. Darrell M. Wilson, S-322, Stanford University Medical Center, Stanford, CA 94305. o 1989 by Grune & Stratton, Inc. 0026-0495/89/3801-0009$03.00/O",

year = "1989",

month = jan,

doi = "10.1016/0026-0495(89)90180-7",

language = "English (US)",

volume = "38",

pages = "57--62",

journal = "Metabolism",

issn = "0026-0495",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion

AU - Wilson, Derrell M.

AU - Perkins, Susan N.

AU - Thomas, James A.

AU - Seelig, Steven

AU - Berry, Susan A

AU - Hamm, Thomas E.

AU - Hoffman, Andrew R.

AU - Hintz, Raymond L.

AU - Rosenfeld, Ron G.

N1 - Funding Information: From the Department of Pediatrics, Medicine, and Laboratory Animal Medicine, Stanford University. Stanford, CA. and the Department of Pediatrics, University of Minnesota, MN. Presented in part to the American Federation of Clinical Research. Western Section, Carmel. CA, February 1987. Supported in part by NIH grant Nos. DK32817. DK38480. lP40RRO3624-01, lR24RRO259601. DK28229, DK36054. AGO1312. and DK24085. and the American Institute for Cancer Research. Dr. Thomas is a recipient of a Science Research Program award of the March of Dimes Birth Defects Foundation. Dr. Rosenfeld is a recipient of a Research Career Development Award from the NIH (DKO1275). Dr. Perkins is a recipient of a NRSA (DKO7768). Address reprint requests to Dr. Darrell M. Wilson, S-322, Stanford University Medical Center, Stanford, CA 94305. o 1989 by Grune & Stratton, Inc. 0026-0495/89/3801-0009$03.00/O

PY - 1989/1

Y1 - 1989/1

N2 - The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P < .0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.

AB - The insulinlike growth factors (IGF) appear to exert feedback control over their own production. In an effort to determine the physiologic mechanisms for this feedback modulation, we utilized a previously developed in vivo model in which rIGF-II secreting tumor cells are transplanted into immunodeficient rats to form IGF-II secreting tumors. The tumor-bearing rat have serum IGF-II concentrations sevenfold greater than those in controls (119 ± 16 ng/mL [mean ± SE] v 17 ± 2 ng/mL, P < .0001). Serum IGF-I concentrations were reduced among the tumor-bearing rats (438 ± 42 ng/mL v 606 ± 32 ng/mL, P = .002) and were negatively correlated with IGF-II concentrations (r = -.47, P = .025), suggesting that IGF-II suppressed the secretion of IGF-I. Increased serum IGF-II concentrations, however, did not affect basal growth hormone concentrations (tumor-bearing, 44 ± 12 ng/mL; control 33 ± 6 ng/mL, P = 0.96). The GH response to GH releasing factor was likewise similar in both groups. Moveover, pituitary GH mRNA level were not different in the two groups, suggesting that IGF-II does not have a significant effect on GH secretion in this in vivo model. There was no association between serum glucose and serum IGF-I or IGF-II concentrations. To examine the effect of IGF-II on IGF-I production from the liver, we measured IGF-I mRNA levels in a subset of animals. Despite these differences in serum IGF-I concentrations, the tumor-bearing rats did not have significantly lower liver IGF-I mRNA levels. These data suggest that IGF-II may act at sites other than the pituitary or liver to alter serum IGF-I concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0024540366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024540366&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(89)90180-7

DO - 10.1016/0026-0495(89)90180-7

M3 - Article

C2 - 2491900

AN - SCOPUS:0024540366

SN - 0026-0495

VL - 38

SP - 57

EP - 62

JO - Metabolism

JF - Metabolism

IS - 1

ER -

Effects of elevated serum insulinlike growth factor-II on growth hormone and insulinlike growth factor-I mRNA and secretion

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this